PCM
ITOS

Penserra Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Penserra Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-805
Closed -$21K – 1450
2021
Q3 		$21K Buy
805
+5
+0.6% +$131 ﹤0.01% 1236
2021
Q2 		$20K Buy
800
+10
+1% +$238 ﹤0.01% 1147
2021
Q1 		$27K Sell
790
-15
-2% -$542 ﹤0.01% 916
2020
Q4 		$27K Buy
+805
New +$21.3K ﹤0.01% 807

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Penserra Capital Management's ITOS Position: Q4 2021 in Review

Penserra Capital Management sold out of iTeos Therapeutics (ITOS) in Q4 2021, closing a stake of 805 shares — an estimated $21K sold.

Penserra Capital Management first reported a position in ITOS in Q4 2020 and held it in 4 quarters. The position peaked at $27K in Q1 2021. 118 funds tracked by Wall St. Rank hold ITOS as of Q4 2021.

  • Penserra Capital Management reported no remaining iTeos Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 805 iTeos Therapeutics shares in Q4 2021, an estimated $21K.
  • Penserra Capital Management first reported a position in iTeos Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's iTeos Therapeutics position peaked at $27K in Q1 2021.
  • 118 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.